Prognostic significance of human epididymis protein 4 in epithelial ovarian cancer

Jemal, 2009, Cancer statistics, 2009, CA Cancer J Clin, 59, 225, 10.3322/caac.20006

Malkasian, 1988, Preoperative evaluation of serum CA 125 levels in premenopausal and postmenopausal patients with pelvic masses: discrimination of benign from malignant disease, Am J Obstet Gynecol, 159, 341, 10.1016/S0002-9378(88)80081-4

Jacobs, 1989, The CA 125 tumour-associated antigen: a review of the literature, Hum Reprod, 4, 1, 10.1093/oxfordjournals.humrep.a136832

Friedlander, 1998, Prognostic factors in ovarian cancer, Semin Oncol, 25, 305

Wang, 1999, Monitoring gene expression profile changes in ovarian carcinomas using cDNA microarray, Gene, 229, 101, 10.1016/S0378-1119(99)00035-9

Galgano, 2006, Comprehensive analysis of HE4 expression in normal and malignant human tissues, Mod Pathol, 19, 847, 10.1038/modpathol.3800612

Hough, 2000, Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer, Cancer Res, 60, 6281

Hough, 2001, Coordinately up-regulated genes in ovarian cancer, Cancer Res, 61, 3869

Drapkin, 2005, Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas, Cancer Res, 65, 2162, 10.1158/0008-5472.CAN-04-3924

Hellstrm, 2003, The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma, Cancer Res, 63, 3695

Moore, 2008, The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass, Gynecol Oncol, 108, 402, 10.1016/j.ygyno.2007.10.017

Scholler, 1999, Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma, Proc Natl Acad Sci USA, 96, 11531, 10.1073/pnas.96.20.11531

Mok, 2001, Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology, J Natl Cancer Inst, 93, 1458, 10.1093/jnci/93.19.1458

Kim, 2002, Osteopontin as a potential diagnostic biomarker for ovarian cancer, JAMA, 287, 1671, 10.1001/jama.287.13.1671

Hwang, 2009, Correlation between preoperative serum levels of five biomarkers and relationships between these biomarkers and cancer stage in epithelial overian cancer, J Gynecol Oncol, 20, 169, 10.3802/jgo.2009.20.3.169

Diamandis, 2000, Human kallikrein 6 (zyme/proteaseM/neurosin): a new serum biomarker of ovarian carcinoma, Clin Biochem, 33, 579, 10.1016/S0009-9120(00)00182-X

Baron, 1999, Serum sErbB1 and epidermal growth factor levels as tumor biomarkers in women with stage III or IV epithelial ovarian cancer, Cancer Epidemiol Biomarkers Prev, 8, 129

Cho, 2009, Mutational analysis of KRAS, BRAF, and TP53 genes of ovarian serous carcinomas in Korean women, Yonsei Med J, 50, 266, 10.3349/ymj.2009.50.2.266

Kim, 2009, Osteopontin, CD44, and NFkappaB expression in gastric adenocarcinoma, Cancer Res Treat, 41, 29, 10.4143/crt.2009.41.1.29

Kirchhoff, 1991, A major human epididymis-specific cDNA encodes a protein with sequence homology to extracellular proteinase inhibitors, Biol Reprod, 45, 350, 10.1095/biolreprod45.2.350

Kirchhoff, 1998, Molecular characterization of epididymal proteins, Rev Reprod, 3, 86, 10.1530/ror.0.0030086

Huhtinen, 2009, Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts, Br J Cancer, 100, 1315, 10.1038/sj.bjc.6605011

Andersen, 2010, Use of a symptom index, CA125, and HE4 to predict ovarian cancer, Gynecol Oncol, 116, 378, 10.1016/j.ygyno.2009.10.087

Niwa, 1994, Alteration of p53 gene in ovarian carcinoma: clinicopathological correlation and prognostic significance, Br J Cancer, 70, 1191, 10.1038/bjc.1994.472

Sood, 1999, Distant metastases in ovarian cancer: association with p53 mutations, Clin Cancer Res, 5, 2485

Anastasi, 2010, HE4: a new potential early biomarker for the recurrence of ovarian cancer, Tumour Biol, 31, 113, 10.1007/s13277-009-0015-y